Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zeria Pharmaceutical CoTSE:4559 +1.61%85 Interest Coverage is 27.44 as of Mar. 2026, which is 33% above its 10-year median of 20.60. GuruFocus rates TSE:4559 with a GF Score™ of 85/100 and a GF Value™ of 円2,506.68 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 687 Drug Manufacturers companies, Zeria Pharmaceutical Co ranks better than 62.15% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Zeria Pharmaceutical Co's
Operating Income
for the
three
months ended in Mar. 2026 was 円3,808 Mil. Zeria Pharmaceutical Co's Interest Expense for the
three
months ended in Mar. 2026 was 円-139 Mil.
Zeria Pharmaceutical Co's interest coverage for the quarter that ended in Mar. 2026 was 27.44.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Zeria Pharmaceutical Co's Interest Coverage or its related term are showing as below:
TSE:4559'
s Interest Coverage Range Over the Past 10 Years
Min: 14.59 Med: 20.6 Max: 26.97
Current: 24.66
TSE:4559's Interest Coverage is ranked better than 62.15% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs TSE:4559: 24.66
Zeria Pharmaceutical Co (TSE:4559) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Zeria Pharmaceutical Co Interest Coverage Related Terms
Zeria Pharmaceutical Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Zeria Pharmaceutical Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TSE:4559 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zeria Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeria Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zeria Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Zeria Pharmaceutical Co's Interest Coverage falls into.
Zeria Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeria Pharmaceutical Co (TSE:4559) has a Interest Coverage of 27.44 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zeria Pharmaceutical Co and its competitors. This is 33% above median its historical median of 20.60. Over the past decade, Zeria Pharmaceutical Co's Interest Coverage has ranged from 14.59 to 26.97. According to the industry distribution chart, Zeria Pharmaceutical Co ranks #260 out of 687 companies in the Drug Manufacturers industry, placing it in the top 37.8%.
Is Zeria Pharmaceutical Co's Interest Coverage too high?
Zeria Pharmaceutical Co's current Interest Coverage of 27.44 is 33% above median its 10-year median of 20.60. Over the past 10 years, this metric has ranged from a low of 14.59 to a high of 26.97. The Drug Manufacturers industry median Interest Coverage is 12.75. Zeria Pharmaceutical Co's value of 27.44 is 115.2% above this industry median. Based on the distribution chart, Zeria Pharmaceutical Co ranks #260 out of 687 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zeria Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zeria Pharmaceutical Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zeria Pharmaceutical Co ranks #260 out of 687 companies for Interest Coverage. This puts Zeria Pharmaceutical Co in the upper half of its industry. The industry median Interest Coverage is 12.75. Zeria Pharmaceutical Co's value of 27.44 is 115.2% above this benchmark. Historically, Zeria Pharmaceutical Co's own Interest Coverage has ranged from 14.59 to 26.97 over the past decade. While the company's 10-year median is 20.60 vs. the industry median of 12.75, Zeria Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zeria Pharmaceutical Co's current Interest Coverage of 27.44 is 115.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zeria Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zeria Pharmaceutical Co's current Interest Coverage is 27.44, which is 33% above median its own 10-year median of 20.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeria Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zeria Pharmaceutical Co (TSE:4559) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,506.68, compared to a current price of 円2,087.00 — trading 16.7% below its estimated fair value. The current Interest Coverage is 27.44, which is 33% above median its 10-year median of 20.60 and 115.2% above the Drug Manufacturers industry median of 12.75. Zeria Pharmaceutical Co's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Zeria Pharmaceutical Co (TSE:4559), the current Interest Coverage is 27.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeria Pharmaceutical Co (TSE:4559) Overvalued in 2026?
Based on GuruFocus' analysis, Zeria Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円2,087.00 is trading 16.7% below its estimated GF Value™ of 円2,506.68.
GuruFocus considers Zeria Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4559:
Interest Coverage: 27.44 (33% above median its 10-year median of 20.60)
GF Value™: 円2,506.68 vs. price of 円2,087.00 (16.7% below fair value)
Industry Position: 115.2% above the Drug Manufacturers median (#260 of 687)
No single metric tells the full story. See the TSE:4559 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeria Pharmaceutical Co Ltd is a Japanese pharmaceutical company. The company through its subsidiaries engages in two business divisions which include ethical pharmaceutical products and consumer healthcare products business division. It principally manufactures, sells, imports and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, reagents, cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, and health equipment.
85GF Score
Get the complete analysis for TSE:4559
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4559 has been successfully added to your 
